Daniel Peckham

List of Publications by Year
in descending order

127	4,730	117625	106344
papers	citations	34 h-index	65 g-index

135	135	135	5671
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Intrapleural Use of Tissue Plasminogen Activator and DNase in Pleural Infection. New England Journal of Medicine, 2011, 365, 518-526.	27.0	624
2	Emergence and spread of a human-transmissible multidrug-resistant nontuberculous mycobacterium. Science, 2016, 354, 751-757.	12.6	462
3	SHORT COMMUNICATION: Glutathione S-transferase GSTT1 genotypes and susceptibility to cancer: studies of interactions with GSTM1 in lung, oral, gastric and colorectal cancers. Carcinogenesis, 1996, 17, 881-884.	2.8	277
4	Recognition, clinical diagnosis and management of patients with primary antibody deficiencies: a systematic review. Clinical and Experimental Immunology, 2007, 149, 410-423.	2.6	194
5	Accurate Assessment of Adherence. Chest, 2011, 140, 425-432.	0.8	179
6	Steady-state pharmacokinetics of intravenous colistin methanesulphonate in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2003, 52, 987-992.	3.0	159
7	European Cystic Fibrosis Society Standards of Care: Framework for the Cystic Fibrosis Centre. Journal of Cystic Fibrosis, 2014, 13, S3-S22.	0.7	153
8	Antibiotic Treatment of Multidrug-Resistant Organisms in Cystic Fibrosis. Treatments in Respiratory Medicine, 2003, 2, 321-332.	1.2	119
9	Neurodegenerative Disease and the NLRP3 Inflammasome. Frontiers in Pharmacology, 2021, 12, 643254.	3.5	107
10	Mass Spectrometric Characterization of Circulating and Functional Antigens Derived from Piperacillin in Patients with Cystic Fibrosis. Journal of Immunology, 2011, 187, 200-211.	0.8	101
11	Alcaligenes infection in cystic fibrosis. Pediatric Pulmonology, 2002, 34, 101-104.	2.0	76
12	Different CFTR modulator combinations downregulate inflammation differently in cystic fibrosis. ELife, 2020, 9, .	6.0	75
13	The global impact of SARS-CoV-2 in 181 people with cystic fibrosis. Journal of Cystic Fibrosis, 2020, 19, 868-871.	0.7	74
14	Characterization of the Antigen Specificity of T-Cell Clones from Piperacillin-Hypersensitive Patients with Cystic Fibrosis. Journal of Pharmacology and Experimental Therapeutics, 2012, 341, 597-610.	2.5	72
15	ENaC-mediated sodium influx exacerbates NLRP3-dependent inflammation in cystic fibrosis. ELife, 2019, 8, .	6.0	70
16	The burgeoning field of innate immuneâ€mediated disease and autoinflammation. Journal of Pathology, 2017, 241, 123-139.	4.5	62
17	Stenotrophomonas maltophilia contamination of nebulizers used to deliver aerosolized therapy to inpatients with cystic fibrosis. Journal of Hospital Infection, 2003, 55, 180-183.	2.9	56
18	The role of respiratory viruses in adult patients with cystic fibrosis receiving intravenous antibiotics for a pulmonary exacerbation. Journal of Cystic Fibrosis, 2014, 13, 49-55.	0.7	54

#	Article	IF	Citations
19	Definition of the Nature and Hapten Threshold of the Î²-Lactam Antigen Required for T Cell Activation In Vitro and in Patients. Journal of Immunology, 2017, 198, 4217-4227.	0.8	54
20	The benefits of 3D modelling and animation in medical teaching. The Journal of Audiovisual Media in Medicine, 2002, 25, 142-148.	0.1	53
21	Î²-Lactam Antibiotics Form Distinct Haptenic Structures on Albumin and Activate Drug-Specific T-Lymphocyte Responses in Multiallergic Patients with Cystic Fibrosis. Chemical Research in Toxicology, 2013, 26, 963-975.	3.3	50
22	Negative Regulation by PD-L1 during Drug-Specific Priming of IL-22â€“Secreting T Cells and the Influence of PD-1 on Effector T Cell Function. Journal of Immunology, 2014, 192, 2611-2621.	0.8	50
23	Pharmacokinetics and safety of itraconazole in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2004, 53, 841-847.	3.0	48
24	Serologic diagnosis of allergic bronchopulmonary aspergillosis in patients with cystic fibrosis through the detection of immunoglobulin G to Aspergillus fumigatus. Diagnostic Microbiology and Infectious Disease, 2008, 62, 287-291.	1.8	45
25	Isolation of the Fungus Geosmithia argillacea in Sputum of People with Cystic Fibrosis. Journal of Clinical Microbiology, 2010, 48, 2615-2617.	3.9	44
26	Enhanced antigenicity leads to altered immunogenicity in sulfamethoxazole-hypersensitive patients with cystic fibrosis. Journal of Allergy and Clinical Immunology, 2011, 127, 1543-1551.e3.	2.9	43
27	Therapeutic drug monitoring of once daily tobramycin in cystic fibrosisâ€”caution with trough concentrations. Journal of Cystic Fibrosis, 2007, 6, 125-130.	0.7	42
28	Dysregulated signalling pathways in innate immune cells with cystic fibrosis mutations. Cellular and Molecular Life Sciences, 2020, 77, 4485-4503.	5.4	42
29	Metabolic Reprograming of Cystic Fibrosis Macrophages via the IRE1Î± Arm of the Unfolded Protein Response Results in Exacerbated Inflammation. Frontiers in Immunology, 2019, 10, 1789.	4.8	41
30	Measurement of urinary N-acetyl-b-d-glucosaminidase in adult patients with cystic fibrosis: Before, during and after treatment with intravenous antibiotics. Journal of Cystic Fibrosis, 2007, 6, 67-73.	0.7	39
31	Nutritional decline in cystic fibrosis related diabetes: The effect of intensive nutritional intervention. Journal of Cystic Fibrosis, 2009, 8, 179-185.	0.7	39
32	Rapid desensitization for non-immediate reactions in patients with cystic fibrosis. Journal of Cystic Fibrosis, 2011, 10, 282-285.	0.7	39
33	COVID-19 meets Cystic Fibrosis: for better or worse?. Genes and Immunity, 2020, 21, 260-262.	4.1	39
34	Dose adjustments of Elexacaftor/Tezacaftor/Ivacaftor in response to mental health side effects in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 1061-1065.	0.7	37
35	Diagnostic and prognostic significance of systemic alkyl quinolones for P. aeruginosa in cystic fibrosis: A longitudinal study. Journal of Cystic Fibrosis, 2017, 16, 230-238.	0.7	36
36	Airborne dissemination of Burkholderia (Pseudomonas) cepacia from adult patients with cystic fibrosis.. Thorax, 1994, 49, 1157-1159.	5.6	35

#	Article	IF	Citations
37	Delayed diagnosis of cystic fibrosis associated with R117H on a background of 7T polythymidine tract at intron 8. Journal of Cystic Fibrosis, 2006, 5, 63-65.	0.7	35
38	Î²-Lactam hypersensitivity involves expansion of circulating and skin-resident TH22Âcells. Journal of Allergy and Clinical Immunology, 2018, 141, 235-249.e8.	2.9	34
39	Nonimmediate Î²-lactam reactions in patients with cystic fibrosis. Current Opinion in Allergy and Clinical Immunology, 2012, 12, 369-375.	2.3	33
40	Long-term safety and efficacy of tezacaftorâ€“ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study. Lancet Respiratory Medicine,the, 2021, 9, 733-746.	10.7	33
41	Serum and sputum concentrations following the oral administration of linezolid in adult patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2004, 53, 325-328.	3.0	31
42	Is Burkholderia (Pseudomonas) cepacia disseminated from cystic fibrosis patients during physiotherapy?. Journal of Hospital Infection, 1996, 32, 9-15.	2.9	29
43	Na+/K+ATPase in Lower Airway Epithelium from Cystic Fibrosis and Non-Cystic-Fibrosis Lung. Biochemical and Biophysical Research Communications, 1997, 232, 464-468.	2.1	29
44	Enteral tube feeding in adults with cystic fibrosis; patient choice and impact on long term outcomes. Journal of Cystic Fibrosis, 2013, 12, 616-622.	0.7	27
45	Fungal contamination of nebuliser devices used by people with cystic fibrosis. Journal of Cystic Fibrosis, 2016, 15, 74-77.	0.7	26
46	Macrolide antibiotics and cystic fibrosis. Thorax, 2002, 57, 189-190.	5.6	25
47	Clinical impact of reducing routine susceptibility testing in chronic Pseudomonas aeruginosa infections in cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2007, 61, 425-427.	3.0	25
48	Autoinflammatory disease in the lung. Immunology, 2018, 154, 563-573.	4.4	25
49	Hydrocephalus and diffuse choroid plexus hyperplasia in primary ciliary dyskinesia-related MCIDAS mutation. Neurology: Genetics, 2020, 6, e482.	1.9	24
50	Use of ceftazidime/avibactam for the treatment of MDR Pseudomonas aeruginosa and Burkholderia cepacia complex infections in cystic fibrosis: a case series. Journal of Antimicrobial Chemotherapy, 2019, 74, 1425-1429.	3.0	23
51	Characterization of Peroxidases Expressed in Human Antigen Presenting Cells and Analysis of the Covalent Binding of Nitroso Sulfamethoxazole to Myeloperoxidase. Chemical Research in Toxicology, 2015, 28, 144-154.	3.3	22
52	An aerobiological model of aerosol survival of different strains of Pseudomonas aeruginosa isolated from people with cystic fibrosis. Journal of Cystic Fibrosis, 2010, 9, 64-68.	0.7	21
53	Level of accuracy of diagnoses recorded in discharge summaries: A cohort study in three respiratory wards. Journal of Evaluation in Clinical Practice, 2019, 25, 36-43.	1.8	21
54	Effect of antibiotic treatment on inflammatory markers and lung function in cystic fibrosis patients with Pseudomonas cepacia.. Thorax, 1994, 49, 803-807.	5.6	20

#	Article	IF	Citations
55	A pilot study of zafirlukast as an anti-inflammatory agent in the treatment of adults with cystic fibrosis. Journal of Cystic Fibrosis, 2003, 2, 25-28.	0.7	20
56	Ten years of viral and non-bacterial serology in adults with cystic fibrosis. Epidemiology and Infection, 2008, 136, 128-134.	2.1	20
57	Variation in lung function as a marker of adherence to oral and inhaled medication in cystic fibrosis. European Respiratory Journal, 2017, 49, 1600987.	6.7	20
58	Average rate of lung function decline in adults with cystic fibrosis in the United Kingdom: Data from the UK CF registry. Journal of Cystic Fibrosis, 2021, 20, 86-90.	0.7	19
59	Effect of oral bisphosphonates on bone mineral density and body composition in adult patients with cystic fibrosis: a pilot study. Thorax, 2004, 59, 699-703.	5.6	18
60	Drug Metabolite-Specific Lymphocyte Responses in Sulfamethoxazole Allergic Patients with Cystic Fibrosis. Chemical Research in Toxicology, 2010, 23, 1009-1011.	3.3	17
61	The impact of three discharge coding methods on the accuracy of diagnostic coding and hospital reimbursement for inpatient medical care. International Journal of Medical Informatics, 2018, 115, 35-42.	3.3	17
62	The development and deployment of integrated electronic care records in a regional adult and paediatric cystic fibrosis unit. Journal of Cystic Fibrosis, 2014, 13, 681-686.	0.7	16
63	Cystic Fibrosis Diagnosis in Newborns, Children, and Adults. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 701-714.	2.1	16
64	Type IV hypersensitivity to vitamin K. Contact Dermatitis, 2002, 46, 94-96.	1.4	15
65	Burkholderia cepacia complex infection in adult patients with cystic fibrosisâ€"is early eradication possible?. Journal of Cystic Fibrosis, 2003, 2, 220-221.	0.7	15
66	Respiratory morbidity in young people surviving cancer: Populationâ€based study of hospital admissions, treatmentâ€related risk factors and subsequent mortality. International Journal of Cancer, 2019, 145, 20-28.	5.1	15
67	Pathogenicity of individual rhinovirus species during exacerbations of cystic fibrosis. European Respiratory Journal, 2015, 45, 1748-1751.	6.7	14
68	Survival of Mycobacterium abscessus isolated from people with cystic fibrosis in artificially generated aerosols. European Respiratory Journal, 2016, 48, 1789-1791.	6.7	14
69	Detection of drugâ€responsive B lymphocytes and antidrug IgG in patients with Î²â€lactam hypersensitivity. Allergy: European Journal of Allergy and Clinical Immunology, 2017, 72, 896-907.	5.7	14
70	Current and future management of non-tuberculous mycobacterial pulmonary disease (NTM-PD) in the UK. BMJ Open Respiratory Research, 2020, 7, e000591.	3.0	14
71	Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case-control study. Journal of Cystic Fibrosis, 2022, 21, 302-308.	0.7	14
72	Higher throughput drug screening for rare respiratory diseases: Readthrough therapy in primary ciliary dyskinesia. European Respiratory Journal, 2021, 58, 2000455.	6.7	13

#	Article	IF	Citations
73	Sequential Bronchoscopy in the Management of Lobar Atelectasis Secondary to Allergic Bronchopulmonary Aspergillosis. Journal of Bronchology and Interventional Pulmonology, 2011, 18, 57-60.	1.4	12
74	Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis. Current Medical Research and Opinion, 2012, 28, 1059-1067.	1.9	12
75	HLAâ€DQ alleleâ€restricted activation of nitroso sulfamethoxazoleâ€specific CD4â€positive T lymphocytes from patients with cystic fibrosis. Clinical and Experimental Allergy, 2015, 45, 1305-1316.	2.9	12
76	Acute Burkholderia cenocepacia pyomyositis in a patient with cystic fibrosis. Journal of Cystic Fibrosis, 2009, 8, 273-275.	0.7	11
77	Drug induced complications; can we do more?. Journal of Cystic Fibrosis, 2013, 12, 547-558.	0.7	11
78	Cystic fibrosis presenting as acute pancreatitis and obstructive azoospermia in a young adult male with a novel mutation in the CFTR gene. Pediatric Pulmonology, 2002, 34, 491-495.	2.0	10
79	Bloodstream infections in cystic fibrosis: Nine years of experience in both adults and children. Journal of Cystic Fibrosis, 2012, 11, 337-339.	0.7	10
80	Assessing arthritis in the context of cystic fibrosis. Pediatric Pulmonology, 2019, 54, 770-777.	2.0	10
81	Serum IgE and IgG reactivity to Aspergillus recombinant antigens in patients with cystic fibrosis. Journal of Medical Microbiology, 2019, 68, 924-929.	1.8	10
82	Oral cysteamine as an adjunct treatment in cystic fibrosis pulmonary exacerbations: An exploratory randomized clinical trial. PLoS ONE, 2020, 15, e0242945.	2.5	10
83	Stenotrophomonas maltophilia Bacteraemia in Two Patients with Cystic Fibrosis Associated with Totally Implantable Venous Access Devices. Journal of Infection, 2002, 44, 53-55.	3.3	9
84	Pharmacokinetics of oral voriconazole in patients with cystic fibrosis. Journal of Antimicrobial Chemotherapy, 2011, 66, 2438-2440.	3.0	9
85	A/H1N1 and other viruses affecting cystic fibrosis. BMJ: British Medical Journal, 2009, 339, b3958-b3958.	2.3	9
86	Implementing ICMH-CF (International Committee on Mental Health in CF) guidance on screening for depression and anxiety symptoms: A feasibility and pilot study. Journal of Cystic Fibrosis, 2016, 15, e33-e34.	0.7	8
87	Electronic patient records, past, present and future. Paediatric Respiratory Reviews, 2016, 20, 8-11.	1.8	8
88	The Perils and Pitfalls of Esophageal Dysmotility in Idiopathic Pulmonary Fibrosis. American Journal of Gastroenterology, 2021, 116, 1189-1200.	0.4	8
89	Treatment of resistant distal intestinal obstruction syndrome with a modified antegrade continence enema procedure. Journal of Cystic Fibrosis, 2004, 3, 273-275.	0.7	7
90	Requirements and access needs of patients with chronic disease to their hospital electronic health record: results of a cross-sectional questionnaire survey. BMJ Open, 2016, 6, e012257.	1.9	7

#	Article	IF	Citations
91	Ultrasound and magnetic resonance imaging assessment of joint disease in symptomatic patients with cystic fibrosis arthropathy. Journal of Cystic Fibrosis, 2016, 15, e35-e40.	0.7	7
92	Assessment of Antipiperacillin IgG Binding to Structurally Related Drug Protein Adducts. Chemical Research in Toxicology, 2017, 30, 2097-2099.	3.3	6
93	Intravenous fosfomycin for pulmonary exacerbation of cystic fibrosis: Real life experience of a large adult CF centre. Pulmonary Pharmacology and Therapeutics, 2018, 50, 82-87.	2.6	6
94	Routine screening for cystic fibrosis-related diabetes. Journal of the Royal Society of Medicine, 2009, 102, 36-39.	2.0	5
95	Cystic fibrosis co-existing with trisomy 21. Journal of Cystic Fibrosis, 2010, 9, 330-331.	0.7	5
96	Nutritional status and pulmonary function in patients with cystic fibrosis with and without Burkholderia cepacia colonization: role of specialist dietetic support. Journal of Human Nutrition and Dietetics, 1996, 9, 173-179.	2.5	4
97	Hypogonadotropic hypogonadism: a consequence of Chiari-I malformation. Pituitary, 2010, 13, 183-185.	2.9	4
98	Presenting life with cystic fibrosis: a Qâ€methodological approach to developing balanced, experienceâ€based prenatal screening information. Health Expectations, 2015, 18, 1349-1362.	2.6	4
99	A treatment evaluator tool to monitor the real-world effectiveness of inhaled aztreonam lysine in cystic fibrosis. Journal of Cystic Fibrosis, 2017, 16, 695-701.	0.7	4
100	Cystic fibrosis-related diabetes (CFRD) and cognitive function in adults with cystic fibrosis. Journal of Cystic Fibrosis, 2022, 21, 519-528.	0.7	4
101	Urinary bicarbonate and metabolic alkalosis during exacerbations in cystic fibrosis. ERJ Open Research, 2022, 8, 00669-2021.	2.6	4
102	Na+ in cystic fibrosis: is it important?. Trends in Pharmacological Sciences, 1995, 16, 120-121.	8.7	3
103	Investigating recurrent respiratory infections in primary care. BMJ: British Medical Journal, 2009, 339, b4118-b4118.	2.3	3
104	Myocardial infarction in an adult with cystic fibrosis and heart and lung transplant. Multidisciplinary Respiratory Medicine, 2013, 8, 37.	1.5	3
105	Diagnostic and prognostic significance of systemic alkyl quinolones for P. aeruginosa in cystic fibrosis: A longitudinal study; response to comments. Journal of Cystic Fibrosis, 2017, 16, e21.	0.7	3
106	Machine Learning Predicts Acute Pulmonary Exacerbations in Cystic Fibrosis. SSRN Electronic Journal, 0, , .	0.4	3
107	Decision Making about Risk of Infection by Young Adults with CF. Pulmonary Medicine, 2013, 2013, 1-6.	1.9	2
108	Characterization of the TCR V repertoire of piperacillinâ€specific Tâ€cells. Clinical and Translational Allergy, 2014, 4, P39.	3.2	2

#	Article	IF	Citations
109	Reply to Professor Taylor. Journal of Cystic Fibrosis, 2014, 13, 486-487.	0.7	2
110	Update on primary ciliary dyskinesia. Paediatrics and Child Health (United Kingdom), 2017, 27, 337-342.	0.4	2
111	Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis. ERJ Open Research, 2018, 4, 00111-2017.	2.6	2
112	Smartphone pedometers in adults with asthma: a practical approach to physical activity assessment? A pilot validation study. Journal of Asthma, 2022, 59, 967-975.	1.7	2
113	Ways of coping and survival in Cystic Fibrosis: a 20-year longitudinal study. Journal of Cystic Fibrosis, 2023, 22, 112-118.	0.7	2
114	An unusual cause of subarachnoid haemorrhage in a patient with newly diagnosed neurofibromatosis: a case report. Cases Journal, 2009, 2, 8399.	0.4	1
115	112â€ƒMusculoskeletal symptoms represent a significant burden for adults with cystic fibrosis. Rheumatology, 2018, 57, .	1.9	1
116	Regulation of the Unfolded Protein Response in Disease: Cellular Stress and microRNAs. Current Immunology Reviews, 2018, 14, 3-14.	1.2	1
117	Nutritional status and intake in patients with non-cystic fibrosis bronchiectasis (NCFB) - a cross sectional study. Clinical Nutrition, 2021, 40, 5162-5168.	5.0	1
118	Can serum bicarbonate be used to screen for sleep disordered breathing (SDB) in obese patients?. , 2018, , .		1
119	Negative regulation by Programmed Death Ligandâ€1 during drugâ€specific priming of Tâ€cells and the influence of Programmed Deathâ€1 on effector Tâ€cell function. Clinical and Translational Allergy, 2014, 4, O2.	3.2	0
120	HLAâ€DQ restricted activation of nitrosoâ€sulfamethoxazoleâ€specific CD4+ Tâ€lymphocytes. Clinical and Translational Allergy, 2014, 4, P110.	3.2	0
121	Antigen exposure required for T cell activation. Clinical and Translational Allergy, 2014, 4, P115.	3.2	0
122	Isoniazidâ€specific Tâ€cell Responses in patients with antiâ€tuberculosis drug related liver injury. Clinical and Translational Allergy, 2014, 4, P116.	3.2	0
123	Systemic quorum sensing signal molecules are biomarkers for current and futureP. aeruginosainfection in cystic fibrosis patients: A longitudinal study. , 2015, , .		0
124	A new score to identify patients who need fitness to fly test. , 2018, , .		0
125	Use of NIV in cystic fibrosis: 10-year experience of a large adult CF centre. , 2019, , .		0
126	Do CT findings of Mycobacterium abscessus infection in patients with Cystic Fibrosis predict outcome?. , 2019, , .		0

#	Article	IF	Citations
127	Outcomes at 6 months following NIV in adults with cystic fibrosis (CF): experience of a large UK centre. , 2019, , .		0